Last reviewed · How we verify
Methyl 3-Pyridinecarboxylate (methyl nicotinate)
Methyl 3-Pyridinecarboxylate, also known as methyl nicotinate, is a small molecule drug in the methyl nicotinate class. It is used to treat joint pain. The commercial status of methyl nicotinate is not specified, but it is approved for use in certain indications. As a methyl nicotinate, it works by stimulating blood flow to the affected area, providing relief from pain and inflammation. However, more information is needed to fully understand its pharmacological properties and safety considerations.
At a glance
| Generic name | methyl nicotinate |
|---|---|
| Drug class | methyl nicotinate |
| Therapeutic area | Pain |
| Phase | FDA-approved |
Approved indications
- Joint pain
Common side effects
Key clinical trials
- Study of the Efficacy and Safety of Nicotinamide in Patients With Liver Fibrosis (NICOFIB) (PHASE2)
- Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics
- Diagnosis of Depressive Disorder Malinger Using the Niacin Skin Response Test (NSRT)
- MDMA-assisted Prolonged Exposure Therapy for Comorbid Alcohol Use Disorder and Post-traumatic Stress Disorder (PHASE2)
- Study of the Effect of 12-week Dietary Supplementation With a Multicomponent Nutritional Supplement on Nails and Skin (NA)
- The Topical Niacin Skin Flush Test in First Episode Psychosis
- Niacin Skin Flush Response in Patients With Schizophrenia (PHASE2,PHASE3)
- Flushing in Social Anxiety Disorder on Seroquel (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Methyl 3-Pyridinecarboxylate CI brief — competitive landscape report
- Methyl 3-Pyridinecarboxylate updates RSS · CI watch RSS
- portfolio CI